Valink Therapeutics

Valink Therapeutics is a biotechnology company developing next-generation bispecific antibody-drug conjugates and multispecific antibody therapeutics for oncology.

Its proprietary discovery platform enables modular assembly of complex antibody formats combining multispecificity, multivalency, and drug conjugation, with a focus on improving tumour targeting and therapeutic index.

The company's pipeline targets solid tumour indications including colorectal cancer, with programmes advancing through preclinical development.